Kenvue Inc. maintained its sales expectations for the year while lowering its profitability target as tariffs raise costs.

Shares of Kenvue rose in early Thursday trading after the maker of Band-Aid, Tylenol, and Listerine reported first-quarter ...

American consumer healthcare company Kenvue is implementing new ways to circumvent a potential tariff-related impact of ...

By Svea Herbst-Bayliss NEW YORK (Reuters) -Billionaire investor Daniel Loeb's hedge fund Third Point on Thursday detailed the ...

Gordon Haskett reports that the judge overseeing the initial California Tylenol lawsuit against Kenvue (KVUE) granted summary ...

Kenvue named Kellanova Chief Financial Officer Amit Banati to that role at the over-the-counter drug maker, replacing current financial chief Paul Ruh, effective May 12. Banati has worked in executive ...

Kenvue Inc. today announced its global efforts in celebration of Kenvue Cares Week, the company’s signature annual volunteer ...

(Reuters) -Kenvue beat analysts' expectations for first-quarter profit and revenue on Thursday, as strong demand for its self ...

Kenvue KVUE-1.09%decrease; red down pointing triangle, the Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new chief financial ...

We expect Kenvue, with the freedom to allocate capital and invest as a stand-alone entity, to focus on its 15 priority brands (including Tylenol, Nicorette, Listerine, and Zyrtec) to drive future ...

Kenvue beat Q1 sales estimates and updated its 2025 forecast as it manages foreign exchange impacts, tariffs, and leadership ...